GAITHERSBURG, Md., Dec. 21, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Mark Twyman to the position of Vice President, Marketing. Mr. Twyman’s efforts will be focused on the commercial launch of the company’s RSV F Vaccine.
Mr. Twyman joins Novavax with more than 20 years of experience commercializing healthcare products including key roles at Merck, MedImmune and Genzyme. His eighteen year tenure at Merck included 12 years in the Merck Vaccine Division, where he held roles of increasing responsibility, including Vice President, Global Marketing for the pediatric vaccine franchise. At MedImmune he served as Vice President and General Manager for the influenza program. Mr. Twyman earned an M.B.A. from The Wharton School of the University of Pennsylvania and a Bachelor of Arts degree from Dickinson College.
“We are delighted to welcome Mark to our team,” said John Trizzino, Senior Vice President, Commercial Operations. “His depth of experience in vaccine marketing and commercialization efforts will be an important asset as Novavax prepares to bring its RSV F Vaccine franchise to market.”
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company’s website, novavax.com.
Contact: Novavax, Inc.Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations
Russo Partners, LLCDavid SchullTodd Davenport, Ph.D.